Business ❯ Pharmaceutical Industry

Drug Companies

Pricing Strategies Market Impact Suizo Argentina Eli Lilly Public Procurement Regulations Corporate Ethics Market Competition Market Dynamics Sun Pharmaceutical Industries Profitability AstraZeneca COVID-19 Treatments GSK Droguería Suizo Argentina Price Agreements Eli Lilly & Company Eli Lilly and Novo Nordisk Market Strategies Market Access Market Trends Novo Nordisk BeOne Medicines Price Reductions Sanofi Distribution Practices Otsuka Pharmaceutical Price Controls Corruption in Business Investment Market Research Lawsuits Bristol Myers Squibb CEOs Investor Relations Stealth BioTherapeutics Leadership

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Phase 3 trials are set to begin this quarter following 48-week topline data showing large placebo-adjusted weight loss.

FDA Grants Priority Review to Otsuka’s ADHD Drug Centanafadine With July 24 Decision Date

FDA Seeks Removal of Suicide Warnings From Saxenda, Wegovy and Zepbound

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

FDA Accepts Sonrotoclax NDA, Grants Priority Review for Relapsed Mantle Cell Lymphoma

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

US-EU Trade Deal Imposes 15% Tariff on European Drugs

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research